A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/198 (2006.01) A61K 31/704 (2006.01) A61P 25/16 (2006.01) A61P 25/28 (2006.01) G01N 33/92 (2006.01)
Patent
CA 2325087
The etiology of various age-related neurological diseases remains unknown. Sporadic forms of Alzheimer's, Parkinson's, and Lou Gehrig's disease have been linked to environmental factors that cause neuronal cell death by either by excitotoxicity or by inducing oxidative stress. Our recent studies have demonstrated that various compounds not previously associated with these diseases, i.e., methionine sulfoximine and sitosterol glucoside, appear to be neurotoxins, likely acting by excitotoxic mechanisms. For these compounds, the primary excitotoxic effect appears to involve glutamate release followed by NMDA receptor activation. Lactate dehydrogenase assays demonstrate that both compounds cause rapid cell death in vitro. In addition, both compounds appear to alter antioxidant defense mechanisms, acting particularly on levels of reduced glutathione (GSH). In vivo application of MSO has historically been linked to behavioral abnormalities, including seizures, in various species. Our recent experiments have demonstrated that mice fed cycad flour containing sitosterol glucoside have severe behavioral abnormalities of motor and cognitive function, as well as significant levels of neurodegeneration in cortex, hippocampus, spinal cord, and other CNS regions measured post mortem. The combined weight of excitotoxic action, in concert to a decline in antioxidant defenses, induced by molecules such as methionine sulfoximine and sitosterol glucoside is hypothesized to be causal to neuronal degeneration in various neurological diseases. Understanding the mechanisms of action of these and functionally related molecules may serve to focus attention on potential neurotoxins present in the human environment. Only once such molecules have been identified, can we begin to design appropriate pharmaceutical strategies to prevent or halt the progression of the age-related neurological diseases. Key Words Glutamate, glutathione, excitoxicity, oxidative stress, methionine sulfoximine, sitosterol glucoside, ALS, Parkinson's disease, Alzheimer's disease, ALS-PDC. Abbreviations ALS, amyotrophic lateral sclerosis; ALS-PDC, ALS-parkinsonism dementia complex; AMPA, .alpha.-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; ATP, adenosine triphosphate; BSSG, .beta.-sitosterol-.beta.-D-glucoside; EAA, excitatory amino acid; GluR, glutamate receptor; GSH, glutathione; LDH, lactate dehydrogenase; MSO, methionine sulfoximine; NMDA, N- methyl-D- aspartate; ROS, reactive oxygen species; SOD, superoxide dismutase.
Shaw Christopher A.
Smart & Biggar
The University Of British Columbia
LandOfFree
Sterol glucosides in disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sterol glucosides in disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sterol glucosides in disease will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1967741